We are almost there ...
India wants to go big with ayurveda exports. But it’s not willing to prove that the medicines are safe.
We rarely make our stories free to read. This one is, so make the most of it.
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
No payment details required
Limited time offer $125 $99 for 1 year
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
The moment my account was withheld, my world of learning came crashing down, but then came a sudden realization.
Short answer: Fairly. But it doesn’t look like they’re going to stop anytime soon.